title: Early treatment improves outcomes in acute hepatitis C virus infection: a meta-analysis.
abstract: Acute hepatitis C virus infection is associated with high rates of spontaneous clearance and variable rates of treatment-induced clearance. The benefit of early treatment versus awaiting spontaneous clearance is unknown, as is the optimal timing of treatment.We performed a MEDLINE and EMBASE search for the time period 1950 to October 2008. All English language abstracts using the search terms acute hepatitis C, hepatitis C and acute and hepatitis C and acute disease or acute infection were reviewed. Bibliographies were reviewed.Twenty-two studies including 1075 patients met the inclusion criteria. The sustained virologic response (SVR) rate for treated patients was 78%, significantly higher than 55.1% in untreated patients (OR = 3.08, 95% CI: 1.8-4.8 P value <0.0001). Mean time from diagnosis to spontaneous clearance was 9.7 weeks (SD 6.5). SVR rates varied inversely with time from acute HCV diagnosis. SVR rates for treatment within 12 weeks was 82.5% (95% CI: 75.6-89.3), significantly better than the clearance rates in untreated patients (P < 0.001). Response rates fell to 66.9% for treatment between 12 and 24 weeks, and decreased further to 62.5% for treatment beyond 24 weeks. Rates of viral clearance in treated patients with acute hepatitis C virus infection were significantly higher than that in untreated patients. Treatment rates were highest when treatment was initiated within 12 weeks of diagnosis. Based on these findings, we would advocate a 12 week period of observation for spontaneous clearance before treatment initiation. If no clearance has occurred by 12 weeks, treatment should be initiated.
authors.affiliation: Gastrointestinal Unit, Massachusetts General Hospital, Boston, MA, USA.
authors.forename: K E
authors.initials: KE
authors.lastname: Corey
authors.forename: J
authors.initials: J
authors.lastname: Mendez-Navarro
authors.forename: E C
authors.initials: EC
authors.lastname: Gorospe
authors.forename: H
authors.initials: H
authors.lastname: Zheng
authors.forename: R T
authors.initials: RT
authors.lastname: Chung
mesh_terms: D000328:Adult; D000368:Aged; D000998:Antiviral Agents / Q000627:therapeutic use*; D005260:Female; D006526:Hepatitis C / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000998:Antiviral Agents
references.citation: J Viral Hepat. 2007 Feb;14(2):116-21
references.pmid: 17244251
references.citation: Hepatology. 2002 Oct;36(4 Pt 1):993-1000
references.pmid: 12297849
references.citation: Gastroenterology. 2006 Mar;130(3):632-8
references.pmid: 16530503
references.citation: Clin Infect Dis. 2005 Jul 1;41 Suppl 1:S14-7
references.pmid: 16265608
references.citation: Hepatology. 2004 Jun;39(6):1721-31
references.pmid: 15185314
references.citation: Clin Gastroenterol Hepatol. 2006 Oct;4(10):1278-82
references.pmid: 16931171
references.citation: J Hepatol. 1994 Nov;21(5):831-6
references.pmid: 7890900
references.citation: Gastroenterology. 2003 Jul;125(1):80-8
references.pmid: 12851873
references.citation: N Engl J Med. 2001 Nov 15;345(20):1452-7
references.pmid: 11794193
references.citation: J Med Virol. 2001 Nov;65(3):505-9
references.pmid: 11596085
references.citation: Hepatology. 2000 Mar;31(3):777-82
references.pmid: 10706572
references.citation: Lancet. 1991 Oct 12;338(8772):914-5
references.pmid: 1681268
references.citation: Medicina (Kaunas). 2008;44(7):510-20
references.pmid: 18695347
references.citation: Hepatology. 2004 May;39(5):1213-9
references.pmid: 15122749
references.citation: Clin Infect Dis. 2007 Sep 1;45(5):583-8
references.pmid: 17682992
references.citation: Aliment Pharmacol Ther. 2004 Jul 1;20(1):15-22
references.pmid: 15225166
references.citation: Hepatology. 2003 Jan;37(1):60-4
references.pmid: 12500189
references.citation: N Engl J Med. 1999 Aug 19;341(8):556-62
references.pmid: 10451460
references.citation: J Infect Dis. 2007 Nov 15;196(10):1474-82
references.pmid: 18008226
references.citation: Ann Intern Med. 2000 Feb 15;132(4):296-305
references.pmid: 10681285
references.citation: J Hepatol. 2005 Mar;42(3):323-8
references.pmid: 15791696
references.citation: J Antimicrob Chemother. 2008 Nov;62(5):860-5
references.pmid: 18776191
references.citation: J Hepatol. 2005 Mar;42(3):329-33
references.pmid: 15710214
references.citation: Hepatology. 2006 May;43(5):923-31
references.pmid: 16628640
references.citation: Hepatology. 2006 Feb;43(2):250-6
references.pmid: 16440367
references.citation: J Hosp Infect. 2007 Sep;67(1):86-91
references.pmid: 17719679
references.citation: Ren Fail. 2007;29(6):731-6
references.pmid: 17763169
references.citation: Dig Liver Dis. 2003 Feb;35(2):104-13
references.pmid: 12747629